Hopkins Scientists Find Antipsychotic Drug Has Anti-HIV Activity

June 10, 1997

Researchers at the Johns Hopkins Children's Center have discovered that some metabolites (breakdown products) of a common antipsychotic drug stop the replication of HIV in human cell cultures. The study was published in the May 13 issue of Schizophrenia Research.

Previous studies of antipsychotic have indicated that many of them possess anti-viral activity; for example, thorazine has been shown to slow the progression of AIDS in HIV-infected patients, and lithium can inhibit the replication of herpes simplex viruses.

"This is consistent with the possibility that viral infections may play a role in schizophrenia and other serious neuropsychiatric diseases,"says lead author Lorraine V. Jones-Brando, part of the Children's Center's Stanley Laboratory for the Study of Schizophrenia and Bipolar Disease.

Brando and colleagues studied clozapine, used in the treatment of approximately 58,000 schizophrenic patients each year, and nine of its metabolites, along with several other antipsychotic drugs.

Four clozapine metabolites inhibited the replication of three different strains of HIV at non-toxic concentrations. However, the effective concentrations of the metabolites were 6,000 times higher than an effective dose of AZT. Coupled with the shortage of information available on the levels of clozapine and its breakdown products in humans, the high concentrations necessary for anti-viral activity make clozapine an unlikely candidate for fighting HIV.

"Though the clozapine metabolites are unlikely to be useful for the treatment of HIV infection," says Jones-Brando, "it is possible they may inhibit the replication of other viruses at much lower concentrations." Preliminary findings by Jones-Brando and others indicate that some breakdown products of clozapine also inhibit Borna virus, which causes a fatal neurological disease.

Other researchers involved in the work were James L. Buthod and Louis E. Holland of IIT Research Institute, Chicago; Robert H. Yolken of the Stanley Laboratory at the Johns Hopkins Children's Center; and E. Fuller Torrey of the Twin Studies Unit at St. Elizabeths, Washington, DC.
-end-

Johns Hopkins Medical Institutions' news releases are available on a PRE-EMBARGOED basis on EurekAlert at http://www.eurekalert.org and from the Office of Communications and Public Affairs' direct e-mail news release service. To enroll, call 410-955-4255 or send e-mail to bpalevic@welchlink.welch.jhu.edu or 76520.560@compuserve.com. On a POST-EMBARGOED basis find them at http://hopkins.med.jhu.edu, http://infonet.welch.jhu.edu/news/news_releases, Newswise at http://www.ari.net/newswise or on CompuServe in the SciNews-MedNews library of the Journalism Forum under file extension ".JHM", Quadnet at http://www.quad-net.com or ScienceDaily at http://www.sciencedaily.com.

Johns Hopkins Medicine

Related Schizophrenia Articles from Brightsurf:

Schizophrenia: When the thalamus misleads the ear
Scientists at the University of Geneva (UNIGE) and the Synapsy National Centre of Competence in Research (NCCR) have succeeded in linking the onset of auditory hallucinations - one of the most common symptoms of schizophrenia - with the abnormal development of certain substructures of a region deep in the brain called the thalamus.

Unlocking schizophrenia
New research, led by Prof. LIU Bing and Prof. JIANG Tianzi from the Institute of Automation of the Chinese Academy of Sciences and their collaborators have recently developed a novel imaging marker that may help in the personalized medicine of psychiatric disorders.

Researchers discover second type of schizophrenia
In a study of more than 300 patients from three continents, over one third had brains that looked similar to healthy people.

New clues into the genetic origins of schizophrenia
The first genetic analysis of schizophrenia in an ancestral African population, the South African Xhosa, appears in the Jan.

Dietary supplement may help with schizophrenia
A dietary supplement, sarcosine, may help with schizophrenia as part of a holistic approach complementing antipsychotic medication, according to a UCL researcher.

Schizophrenia: Adolescence is the game-changer
Schizophrenia may be related to the deletion syndrome. However, not everyone who has the syndrome necessarily develops psychotic symptoms.

Study suggests overdiagnosis of schizophrenia
In a small study of patients referred to the Johns Hopkins Early Psychosis Intervention Clinic (EPIC), Johns Hopkins Medicine researchers report that about half the people referred to the clinic with a schizophrenia diagnosis didn't actually have schizophrenia.

The ways of wisdom in schizophrenia
Researchers at UC San Diego School of Medicine report that persons with schizophrenia scored lower on a wisdom assessment than non-psychiatric comparison participants, but that there was considerable variability in levels of wisdom, and those with higher scores displayed fewer psychotic symptoms.

Recognizing the uniqueness of different individuals with schizophrenia
Individuals diagnosed with schizophrenia differ greatly from one another. Researchers from Radboud university medical center, along with colleagues from England and Norway, have demonstrated that very few identical brain differences are shared amongst different patients.

Resynchronizing neurons to erase schizophrenia
Today, a decisive step in understanding schizophrenia has been taken.

Read More: Schizophrenia News and Schizophrenia Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.